辅助性西米普利单抗在高危皮肤鳞状细胞癌中的作用
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.
作者信息
Lim Annette M, Porceddu Sandro, Rischin Danny
机构信息
Department of Medical Oncology, Peter MacCallum Cancer Centre, 3000 Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, 3000 Melbourne, Australia.
出版信息
Curr Oncol. 2025 Aug 15;32(8):459. doi: 10.3390/curroncol32080459.
Abstract
Despite cutaneous squamous cell carcinoma (CSCC) being the second most common skin cancer worldwide, there were no approved systemic therapies for patients with unresectable and/or metastatic disease prior to the advent of anti-programmed cell death protein-1 (anti-PD1) agents cemiplimab and pembrolizumab [...].
摘要
尽管皮肤鳞状细胞癌（CSCC）是全球第二常见的皮肤癌，但在抗程序性细胞死亡蛋白1（抗PD1）药物西米普利单抗和帕博利珠单抗出现之前，对于不可切除和/或转移性疾病患者，尚无获批的全身治疗方法[……]
相似文献
1
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.辅助性西米普利单抗在高危皮肤鳞状细胞癌中的作用
Curr Oncol. 2025 Aug 15;32(8):459. doi: 10.3390/curroncol32080459.
2
Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma-A Systematic Review.新辅助西米普利单抗治疗皮肤鳞状细胞癌的疗效——一项系统评价
Int J Mol Sci. 2025 Aug 21;26(16):8109. doi: 10.3390/ijms26168109.
3
Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma.基线D-二聚体作为西米普利单抗治疗皮肤鳞状细胞癌疗效的预测标志物。
Eur J Cancer. 2025 Aug 26;226:115639. doi: 10.1016/j.ejca.2025.115639. Epub 2025 Jul 10.
4
Cemiplimab in the treatment of metastatic basal cell carcinoma.西米普利单抗治疗转移性基底细胞癌。
Future Oncol. 2025 Jul;21(16):1999-2005. doi: 10.1080/14796694.2025.2511568. Epub 2025 May 27.
5
Cemiplimab-Induced Vogt-Koyanagi-Harada-Like Syndrome in a Patient With Cutaneous Squamous Cell Carcinoma of the Lower Back.西米普利单抗诱发一名下背部皮肤鳞状细胞癌患者出现类小柳原田综合征。
J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251355151. doi: 10.1177/23247096251355151. Epub 2025 Jun 28.
6
Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab.对西米普利单抗有不同反应的晚期皮肤鳞状细胞癌的临床和组织病理学特征
J Dtsch Dermatol Ges. 2025 Jan;23(1):30-37. doi: 10.1111/ddg.15551. Epub 2024 Nov 3.
7
Cemiplimab in advanced cutaneous squamous cell carcinoma.西妥昔单抗联合紫杉醇治疗晚期皮肤鳞状细胞癌的随机对照临床研究
Dermatol Ther. 2021 Nov;34(6):e15184. doi: 10.1111/dth.15184. Epub 2021 Nov 8.
8
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.高危皮肤鳞状细胞癌辅助使用西米普利单抗或安慰剂
N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2502449.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic Approaches.高级别皮肤鳞状细胞癌：意大利多中心回顾性患者特征和治疗方法分析。
Dermatology. 2023;239(3):422-428. doi: 10.1159/000528555. Epub 2023 Mar 15.
本文引用的文献
1
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.高危皮肤鳞状细胞癌辅助使用西米普利单抗或安慰剂
N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2502449.
2
Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial.在皮肤鳞状细胞癌深度测序（DISCERN）试验中，新辅助西米普利单抗治疗II-IV期皮肤鳞状细胞癌的放射学、病理学和手术结果
Cancers (Basel). 2025 May 21;17(10):1727. doi: 10.3390/cancers17101727.
3
Enhanced metastatic risk stratification for cutaneous squamous cell carcinoma by combining clinical guidelines with the Erasmus MC model: Results from 2 nationwide nested case-control studies.通过将临床指南与伊拉斯姆斯医学中心模型相结合增强皮肤鳞状细胞癌转移风险分层：两项全国性巢式病例对照研究的结果
J Am Acad Dermatol. 2025 Sep;93(3):699-706. doi: 10.1016/j.jaad.2025.05.1390. Epub 2025 May 16.
4
Grading differentiation in cutaneous squamous cell carcinoma: A modified Delphi consensus panel.皮肤鳞状细胞癌的分级分化：一个改良的德尔菲共识小组。
J Am Acad Dermatol. 2025 Sep;93(3):781-784. doi: 10.1016/j.jaad.2025.05.003. Epub 2025 May 8.
5
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.西米普利单抗治疗晚期皮肤鳞状细胞癌患者的2期开放标签研究（EMPOWER-CSCC-1）：1、2和3组的最终长期分析以及固定剂量治疗组6的初步分析
J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7.
6
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.新辅助纳武利尤单抗和伊匹单抗治疗可切除 III 期黑色素瘤。
N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2.
7
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.新辅助西妥昔单抗联合手术治疗 II-IV 期皮肤鳞状细胞癌：一项单臂、多中心、Ⅱ期研究的随访和生存结果。
Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21.
8
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.欧洲基于共识的浸润性皮肤鳞状细胞癌跨学科指南。第1部分：诊断与预防 - 2023年更新版
Eur J Cancer. 2023 Nov;193:113251. doi: 10.1016/j.ejca.2023.113251. Epub 2023 Jul 28.
9
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.欧洲基于共识的浸润性皮肤鳞状细胞癌跨学科指南：第2部分。治疗——2023年更新版
Eur J Cancer. 2023 Nov;193:113252. doi: 10.1016/j.ejca.2023.113252. Epub 2023 Jul 28.
10
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.新辅助西米普利单抗治疗晚期可切除头颈部皮肤鳞状细胞癌患者的疗效：一项2期临床试验的二次分析
JAMA Otolaryngol Head Neck Surg. 2023 Sep 1;149(9):847-849. doi: 10.1001/jamaoto.2023.1729.
Zotero 插件